Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 Self-monitoring blood glucose devices (Value and Volume, 2012-2025)
5.1.1 By Component
5.1.1.1 Glucometer Devices
5.1.1.2 Test Strips
5.1.1.3 Lancets
5.1.2 By End User
5.1.2.1 Hospital (Value and Volume, 2012-2025)
5.1.2.1.1 Glucometer Devices
5.1.2.1.2 Test Strips
5.1.2.1.3 Lancets
5.1.2.2 Personal (Value and Volume, 2012-2025)
5.1.2.2.1 Glucometer Devices
5.1.2.2.2 Test Strips
5.1.2.2.3 Lancets
5.2 Continuous blood glucose monitoring devices (Value and Volume, 2012-2025)
5.2.1 By Component
5.2.1.1 Sensors
5.2.1.2 Receivers
5.3 Geography
5.3.1 North America
5.3.1.1 United States (Value and Volume, 2012-2025)
5.3.1.1.1 Self-monitoring blood glucose devices
5.3.1.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.1.1.1.2 By End User (Hospital and Personal)
5.3.1.1.2 Continuous Glucose Monitoring devices
5.3.1.1.2.1 By Component (Sensors and Receivers)
5.3.1.2 Canada (Value and Volume, 2012-2025)
5.3.1.2.1 Self-monitoring blood glucose devices
5.3.1.2.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.1.2.1.2 By End User (Hospital and Personal)
5.3.1.2.2 Continuous Glucose Monitoring
5.3.1.2.2.1 By Component (Sensors and Receivers)
5.3.1.3 Rest of North America (Value and Volume, 2012-2025)
5.3.1.3.1 Self-monitoring blood glucose devices
5.3.1.3.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.1.3.1.2 By End User (Hospital and Personal)
5.3.1.3.2 Continuous Glucose Monitoring
5.3.1.3.2.1 By Component (Sensors and Receivers)
5.3.2 Europe
5.3.2.1 France (Value and Volume, 2012-2025)
5.3.2.1.1 Self-monitoring blood glucose devices
5.3.2.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.2.1.1.2 By End User (Hospital and Personal)
5.3.2.1.2 Continuous Glucose Monitoring
5.3.2.1.2.1 By Component (Sensors and Receivers)
5.3.2.2 Germany (Value and Volume, 2012-2025)
5.3.2.2.1 Self-monitoring blood glucose devices
5.3.2.2.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.2.2.1.2 By End User (Hospital and Personal)
5.3.2.2.2 Continuous Glucose Monitoring
5.3.2.2.2.1 By Component (Sensors and Receivers)
5.3.2.3 Italy (Value and Volume, 2012-2025)
5.3.2.3.1 Self-monitoring blood glucose devices
5.3.2.3.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.2.3.1.2 By End User (Hospital and Personal)
5.3.2.3.2 Continuous Glucose Monitoring
5.3.2.3.2.1 By Component (Sensors and Receivers)
5.3.2.4 Spain (Value and Volume, 2012-2025)
5.3.2.4.1 Self-monitoring blood glucose devices
5.3.2.4.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.2.4.1.2 By End User (Hospital and Personal)
5.3.2.4.2 Continuous Glucose Monitoring
5.3.2.4.2.1 By Component (Sensors and Receivers)
5.3.2.5 United Kingdom (Value and Volume, 2012-2025)
5.3.2.5.1 Self-monitoring blood glucose devices
5.3.2.5.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.2.5.1.2 By End User (Hospital and Personal)
5.3.2.5.2 Continuous Glucose Monitoring
5.3.2.5.2.1 By Component (Sensors and Receivers)
5.3.2.6 Russia (Value and Volume, 2012-2025)
5.3.2.6.1 Self-monitoring blood glucose devices
5.3.2.6.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.2.6.1.2 By End User (Hospital and Personal)
5.3.2.6.2 Continuous Glucose Monitoring
5.3.2.6.2.1 By Component (Sensors and Receivers)
5.3.2.7 Rest of Europe (Value and Volume, 2012-2025)
5.3.2.7.1 Self-monitoring blood glucose devices
5.3.2.7.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.2.7.1.2 By End User (Hospital and Personal)
5.3.2.7.2 Continuous Glucose Monitoring
5.3.2.7.2.1 By Component (Sensors and Receivers)
5.3.3 Latin America
5.3.3.1 Mexico (Value and Volume, 2012-2025)
5.3.3.1.1 Self-monitoring blood glucose devices
5.3.3.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.3.1.1.2 By End User (Hospital and Personal)
5.3.3.1.2 Continuous Glucose Monitoring
5.3.3.1.2.1 By Component (Sensors and Receivers)
5.3.3.2 Brazil (Value and Volume, 2012-2025)
5.3.3.2.1 Self-monitoring blood glucose devices
5.3.3.2.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.3.2.1.2 By End User (Hospital and Personal)
5.3.3.2.2 Continuous Glucose Monitoring
5.3.3.2.2.1 By Component (Sensors and Receivers)
5.3.3.3 Rest of Latin America (Value and Volume, 2012-2025)
5.3.3.3.1 Self-monitoring blood glucose devices
5.3.3.3.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.3.3.1.2 By End User (Hospital and Personal)
5.3.3.3.2 Continuous Glucose Monitoring
5.3.3.3.2.1 By Component (Sensors and Receivers)
5.3.4 Asia-Pacific
5.3.4.1 Japan (Value and Volume, 2012-2025)
5.3.4.1.1 Self-monitoring blood glucose devices
5.3.4.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.4.1.1.2 By End User (Hospital and Personal)
5.3.4.1.2 Continuous Glucose Monitoring
5.3.4.1.2.1 By Component (Sensors and Receivers)
5.3.4.2 South Korea (Value and Volume, 2012-2025)
5.3.4.2.1 Self-monitoring blood glucose devices
5.3.4.2.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.4.2.1.2 By End User (Hospital and Personal)
5.3.4.2.2 Continuous Glucose Monitoring
5.3.4.2.2.1 By Component (Sensors and Receivers)
5.3.4.3 China (Value and Volume, 2012-2025)
5.3.4.3.1 Self-monitoring blood glucose devices
5.3.4.3.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.4.3.1.2 By End User (Hospital and Personal)
5.3.4.3.2 Continuous Glucose Monitoring
5.3.4.3.2.1 By Component (Sensors and Receivers)
5.3.4.4 India (Value and Volume, 2012-2025)
5.3.4.4.1 Self-monitoring blood glucose devices
5.3.4.4.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.4.4.1.2 By End User (Hospital and Personal)
5.3.4.4.2 Continuous Glucose Monitoring
5.3.4.4.2.1 By Component (Sensors and Receivers)
5.3.4.5 Australia (Value and Volume, 2012-2025)
5.3.4.5.1 Self-monitoring blood glucose devices
5.3.4.5.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.4.5.1.2 By End User (Hospital and Personal)
5.3.4.5.2 Continuous Glucose Monitoring
5.3.4.5.2.1 By Component (Sensors and Receivers)
5.3.4.6 Vietnam (Value and Volume, 2012-2025)
5.3.4.6.1 Self-monitoring blood glucose devices
5.3.4.6.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.4.6.1.2 By End User (Hospital and Personal)
5.3.4.6.2 Continuous Glucose Monitoring
5.3.4.6.2.1 By Component (Sensors and Receivers)
5.3.4.7 Malaysia (Value and Volume, 2012-2025)
5.3.4.7.1 Self-monitoring blood glucose devices
5.3.4.7.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.4.7.1.2 By End User (Hospital and Personal)
5.3.4.7.2 Continuous Glucose Monitoring
5.3.4.7.2.1 By Component (Sensors and Receivers)
5.3.4.8 Indonesia (Value and Volume, 2012-2025)
5.3.4.8.1 Self-monitoring blood glucose devices
5.3.4.8.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.4.8.1.2 By End User (Hospital and Personal)
5.3.4.8.2 Continuous Glucose Monitoring
5.3.4.8.2.1 By Component (Sensors and Receivers)
5.3.4.9 Philippines (Value and Volume, 2012-2025)
5.3.4.9.1 Self-monitoring blood glucose devices
5.3.4.9.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.4.9.1.2 By End User (Hospital and Personal)
5.3.4.9.2 Continuous Glucose Monitoring
5.3.4.9.2.1 By Component (Sensors and Receivers)
5.3.4.10 Thailand (Value and Volume, 2012-2025)
5.3.4.10.1 Self-monitoring blood glucose devices
5.3.4.10.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.4.10.1.2 By End User (Hospital and Personal)
5.3.4.10.2 Continuous Glucose Monitoring
5.3.4.10.2.1 By Component (Sensors and Receivers)
5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2025)
5.3.4.11.1 Self-monitoring blood glucose devices
5.3.4.11.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.4.11.1.2 By End User (Hospital and Personal)
5.3.4.11.2 Continuous Glucose Monitoring
5.3.4.11.2.1 By Component (Sensors and Receivers)
5.3.5 Middle East and Africa
5.3.5.1 Saudi Arabia (Value and Volume, 2012-2025)
5.3.5.1.1 Self-monitoring blood glucose devices
5.3.5.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.5.1.1.2 By End User (Hospital and Personal)
5.3.5.1.2 Continuous Glucose Monitoring
5.3.5.1.2.1 By Component (Sensors and Receivers)
5.3.5.2 Iran (Value and Volume, 2012-2025)
5.3.5.2.1 Self-monitoring blood glucose devices
5.3.5.2.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.5.2.1.2 By End User (Hospital and Personal)
5.3.5.2.2 Continuous Glucose Monitoring
5.3.5.2.2.1 By Component (Sensors and Receivers)
5.3.5.3 Egypt (Value and Volume, 2012-2025)
5.3.5.3.1 Self-monitoring blood glucose devices
5.3.5.3.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.5.3.1.2 By End User (Hospital and Personal)
5.3.5.3.2 Continuous Glucose Monitoring
5.3.5.3.2.1 By Component (Sensors and Receivers)
5.3.5.4 Oman (Value and Volume, 2012-2025)
5.3.5.4.1 Self-monitoring blood glucose devices
5.3.5.4.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.5.4.1.2 By End User (Hospital and Personal)
5.3.5.4.2 Continuous Glucose Monitoring
5.3.5.4.2.1 By Component (Sensors and Receivers)
5.3.5.5 South Africa (Value and Volume, 2012-2025)
5.3.5.5.1 Self-monitoring blood glucose devices
5.3.5.5.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.5.5.1.2 By End User (Hospital and Personal)
5.3.5.5.2 Continuous Glucose Monitoring
5.3.5.5.2.1 By Component (Sensors and Receivers)
5.3.5.6 Rest of Middle and Africa (Value and Volume, 2012-2025)
5.3.5.6.1 Self-monitoring blood glucose devices
5.3.5.6.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.5.6.1.2 By End User (Hospital and Personal)
5.3.5.6.2 Continuous Glucose Monitoring
5.3.5.6.2.1 By Component (Sensors and Receivers)


6 MARKET INDICATORS
6.1 Type-1 Diabetes population (2012-2025)
6.2 Type-2 Diabetes population (2012-2025)


7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Abbott Diabetes Care
7.1.1.1 Overview
7.1.1.2 Products and Strategies
7.1.1.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.1.4 Ratio Analysis (5 Years)
7.1.1.5 Strength and Stability Analysis (5 Years)
7.1.1.6 Recent Developments
7.1.2 Roche
7.1.2.1 Overview
7.1.2.2 Products and Strategies
7.1.2.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.2.4 Ratio Analysis (5 Years)
7.1.2.5 Strength and Stability Analysis (5 Years)
7.1.2.6 Recent Developments
7.1.3 Johnson & Johnson
7.1.3.1 Overview
7.1.3.2 Products and Strategies
7.1.3.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.3.4 Ratio Analysis (5 Years)
7.1.3.5 Strength and Stability Analysis (5 Years)
7.1.3.6 Recent Developments
7.1.4 Dexcom
7.1.4.1 Overview
7.1.4.2 Products and Strategies
7.1.4.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.4.4 Ratio Analysis (5 Years)
7.1.4.5 Strength and Stability Analysis (5 Years)
7.1.4.6 Recent Developments
7.1.5 Medtronic
7.1.5.1 Overview
7.1.5.2 Products and Strategies
7.1.5.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.5.4 Ratio Analysis (5 Years)
7.1.5.5 Strength and Stability Analysis (5 Years)
7.1.5.6 Recent Developments
7.1.6 Arkray
7.1.6.1 Overview
7.1.6.2 Products and Strategies
7.1.6.3 Recent Developments
7.1.7 Ascensia Diabetes Care
7.1.7.1 Overview
7.1.7.2 Products and Strategies
7.1.7.3 Recent Developments
7.1.8 Agamatrix Inc.
7.1.8.1 Overview
7.1.8.2 Products and Strategies
7.1.8.3 Recent Developments
7.1.9 Bionime Corporation
7.1.9.1 Overview
7.1.9.2 Products and Strategies
7.1.9.3 Recent Developments
7.1.10 Acon
7.1.10.1 Overview
7.1.10.2 Products and Strategies
7.1.10.3 Recent Developments
7.1.11 Medisana
7.1.11.1 Overview
7.1.11.2 Products and Strategies
7.1.11.3 Recent Developments
7.1.12 Trivida
7.1.12.1 Overview
7.1.12.2 Products and Strategies
7.1.12.3 Recent Developments
7.1.13 Rossmax
7.1.13.1 Overview
7.1.13.2 Products and Strategies
7.1.13.3 Recent Developments
7.2 COMPANY SHARE ANALYSIS
7.2.1 Roche
7.2.2 Johnson & Johnson
7.2.3 Abbott Diabetes Care
7.2.4 Dexcom
7.2.5 Medtronics
7.2.6 Others


8 MARKET OPPORTUNITIES AND FUTURE TRENDS